Omega Fund Management, LLC Long-Term Concentrated

Location: Boston, MA

CIK: 0001637359 · Show all filings

Period: Q4 2014 (Next →)

Filing Date: Mar 23, 2015

Total Value: $217M (100.0% shares, 0.0% debt)

Holdings (7)

— Paratek Pharmaceuticals, Inc. 37.9%

Value $82.45M Shares 2,138,872 Est. Cost $38.55 Unrealized —

— Juno Therapeutics 34.2%

Value $74.41M Shares 1,425,000 Est. Cost $52.22 Unrealized —

— FibroGen, Inc. 12.2%

Value $26.58M Shares 972,175 Est. Cost $27.34 Unrealized —

— Egalet 6.9%

Value $15.05M Shares 2,645,558 Est. Cost $5.69 Unrealized —

— Achaogen Inc. 3.9%

Value $8.573M Shares 656,899 Est. Cost $13.05 Unrealized —

— Dicerna Pharmaceuticals 3.5%

Value $7.716M Shares 468,471 Est. Cost $16.47 Unrealized —

— Proteon Therapeutics 1.2%

Value $2.6M Shares 250,000 Est. Cost $10.40 Unrealized —

Ticker	Issuer	Shares	Value	%	Est. Cost	Unrealized	Class	CUSIP
—	Paratek Pharmaceuticals, Inc.	2,138,872	$82.45M	37.9%	$38.55	—	Common Stock	699374302
—	Juno Therapeutics	1,425,000	$74.41M	34.2%	$52.22	—	Common Stock	48205A109
—	FibroGen, Inc.	972,175	$26.58M	12.2%	$27.34	—	Common Stock	31572Q808
—	Egalet	2,645,558	$15.05M	6.9%	$5.69	—	Common Stock	28226B104
—	Achaogen Inc.	656,899	$8.573M	3.9%	$13.05	—	Common Stock	004449104
—	Dicerna Pharmaceuticals	468,471	$7.716M	3.5%	$16.47	—	Common Stock	253031108
—	Proteon Therapeutics	250,000	$2.6M	1.2%	$10.40	—	Common Stock	74371L109